T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Conditions:   Esophageal Carcinoma;   Malignant Melanoma;   Urothelial Cancer;   Cervical Cancer;   Breast Cancer;   Sarcoma
Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2015

from #ORL via xlomafota13 on Inoreader http://ift.tt/1KHjCUl
via IFTTT